BLA 022542 · Viokace
Viokace
Pancrelipase (Amylase, Lipase, Protease) · Oral
Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Mar 1, 2012
Approved uses
1
Original approval plus efficacy supplements
Registered trials
n/a
n/a Phase 3, n/a recruiting
FAERS reports
2,537
2,257 serious, 286 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 14, 2025.
1. INDICATIONS AND USAGE VIOKACE, in combination with a proton pump inhibitor, is indicated for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy in adults. VIOKACE, in combination with a proton pump inhibitor, is indicated for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy in adults. ( 1 )
Mechanism: Pancreatic enzyme products contain a mixture of lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglycerides, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 1, 2012 Original approval · Type 7 - Drug Already Marketed without Approved NDA LabelReviewLetter
2 products under this application
- VIOKACE · PANCRELIPASE (AMYLASE 39,150USP UNITS; LIPASE 10,440USP UNITS; PROTEASE) 39,150USP UNITS · TABLET, ORAL · Prescription
- VIOKACE · PANCRELIPASE (AMYLASE 78,300USP UNITS; LIPASE 20,880USP UNITS; PROTEASE) 78,300USP UNITS · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pancrelipase (Amylase" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea256
- nausea158
- dyspnoea135
- fatigue133
- off label use131
- vomiting126
- abdominal pain118
- asthenia118
- pyrexia115
- pain108
- weight decreased107
- drug ineffective98
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 16 |
| 2006 | 10 |
| 2007 | 13 |
| 2008 | 12 |
| 2009 | 21 |
| 2010 | 45 |
| 2011 | 49 |
| 2012 | 53 |
| 2013 | 66 |
| 2014 | 56 |
| 2015 | 93 |
| 2016 | 98 |
| 2017 | 103 |
| 2018 | 118 |
| 2019 | 141 |
| 2020 | 170 |
| 2021 | 235 |
| 2022 | 271 |
| 2023 | 260 |
| 2024 | 276 |
| 2025 | 269 |
| 2026 | 140 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Viokace (Lipase/Protease/Amylase)
2024 spending
$2.7M
Beneficiaries
679
2,062 claims
Per beneficiary
$3,981
$5.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $1,743,703 |
| 2022 | $2,824,115 |
| 2023 | $2,582,612 |
| 2024 | $2,703,061 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Viokace
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.